Finding a new way to protect brain cells in Alzheimer's disease
Identification of the Neuroprotective STX Receptor in the Brain
This study is looking at a new treatment called STX that could help protect brain cells in people with Alzheimer's disease without the side effects of traditional estrogen therapies, aiming to improve brain health and function.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10747420 on NIH RePORTER |
What this research studies
This research investigates a novel compound called STX that targets a specific receptor in the brain to provide neuroprotection for patients with Alzheimer's disease. Unlike traditional estrogen therapies, STX does not activate classical estrogen receptors, which helps avoid negative side effects. The study aims to understand how STX can improve brain cell function and protect against damage caused by amyloid proteins, which are harmful in Alzheimer's. Patients may benefit from this approach through improved treatment options that enhance brain health and function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly postmenopausal women who may have lost neuroprotective effects from estrogen.
Not a fit: Patients with early-stage Alzheimer's or those not diagnosed with the disease may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that protects brain cells and improves cognitive function in Alzheimer's patients.
How similar studies have performed: While there have been many studies targeting amyloid plaques, this approach using STX is novel and has not been extensively tested in clinical settings.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Kelly, Martin Jeffrey — Oregon Health & Science University
- Study coordinator: Kelly, Martin Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.